4:02 AM
Jan 29, 2019
 |  BC Extra  |  Clinical News

OncoCyte's lung cancer liquid biopsy test shows 90% sensitivity

Editor's Note: This article was updated on Jan 29, 2019 at 2:02 PM PST

OncoCyte Corp. (NYSE-A:OCX) said Tuesday its DetermaVu liquid biopsy test detected lung cancer with sensitivity of 90% and specificity of 75% in the prospective R&D Validation study in 250 patient blood samples. The news sent the company’s shares soaring $4.09 (225%) to $5.91.

BioTime Inc. (NYSE-A:BTX; Tel Aviv:BTX), which...

Read the full 221 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >